57 results about "Cytokine expression" patented technology

The invention provides a tumor detection data analysis method based on a peripheral blood immune marker, and belongs to the technical field of immunodetection.The tumor detection data analysis method comprises the steps that firstly, a peripheral blood sample of a patient is collected, and plasma and cell components are separated; analyzing various immune cell phenotypes by using flow cytometry; determining the concentration of key cell factors; analyzing the molecular expression level of the immune checkpoint; establishing an immune cell subset proportion empirical function; analyzing a cell factor expression mode by using an immune lineage transcriptome analysis model; establishing a tumor immune microenvironment score by combining the immune cell subset proportion and a model output result; the accuracy of the scoring system is verified through clinical follow-up visit and iconography examination; a standardized report template is formulated to provide a tumor early detection basis. Wherein the immune lineage transcriptome analytical model adopts a multi-modal attention fusion network architecture, three different immune data streams can be processed and integrated at the same time, and accurate evaluation of tumor-related immune states is realized.

The invention belongs to the field of cell biology, particularly relates to stem cell exosome repair gel and a preparation method thereof, and more particularly relates to stem cell exosome repair gel containing active biological peptide and a preparation method thereof. The invention provides a repairing composition which comprises an active peptide as shown in SEQ ID NO.1 and a stem cell exosome. The repair gel provided by the invention contains the active peptide and the stem cell exosome loaded with the bioactive substances, and the components have a synergistic effect, so that the expression level of related cell factors can be improved, the repair after skin injury is promoted, and the physiological state of the skin is improved.

A fermentation process is disclosed that produces an immunomodulatory product. The process includes combining a source of starch, a source of sugar, and a source of a trace mineral with probiotic microorganisms and fermenting aerobically and anaerobically, thereby producing an immunomodulatory product. Turmeric is added before or after fermentation. The immunomodulatory product is also disclosed. Also provided are uses of the immunomodulatory product, such as to decrease inflammation in a subject. These methods can include increasing function of natural killer cells, decreasing T cell activation, altering CD69 expression on immune cells, and / or altering cytokine expression in a subject.

The present disclosure provides engineered induced pluripotent stem cells (iPSCs) expressing B2M-HLA fusion constructs. The present disclosure also provides iPSC-derived macrophages which overexpress IL-12. The present disclosure further provides engineered immune cells having persistent cytokine expression.

The use of formononetin (FMN) in reducing imiquimod (IMQ)-induced inflammatory cytokine expression by means of inhibiting an interferon (IFN) signaling pathway. The FMN can be used for the prevention and treatment of inflammatory skin diseases and the reduction of disease recurrence in the future. Using animal experiments combined with transcriptomics, it is found that the action of FMN on an IMQ-induced mouse model significantly improves inflammatory skin lesion symptoms, and inhibits pathological phenotypes such as the PASI score and epidermal hyperplasia in mice.

The invention belongs to the technical field of microorganisms, and particularly relates to application of a staphylococcus epidermidis H62-3 viable bacterium preparation in preparation of a medicine for preventing or treating psoriasis. Experimental results show that the staphylococcus epidermidis H62-3 viable bacterium preparation improves skin erythema and scale symptoms of a psoriasis mouse model, remarkably reduces the skin lesion thickness, reduces the mRNA expression level of cytokines related to psoriasis at the skin lesion position of the psoriasis mouse model, and improves the psoriasis resistance of the psoriasis mouse model. And the cell factors comprise interleukin-17A, interleukin-17F and interleukin-23. The invention also discloses a preparation method of the cell factor. Therefore, the staphylococcus epidermidis H62-3 viable bacterium preparation has the prospect of being developed into the medicine for preventing or treating psoriasis.

The invention provides a method for evaluating eye irritation in vitro and application thereof, and belongs to the technical field of non-animal test methods. According to the method provided by the invention, a recombinant human corneal epithelium model is utilized, and relative tissue activity RTV and relative cell factor expression quantity RCL are used for comprehensively evaluating the eye irritation of a to-be-detected sample; the method specifically comprises the following steps: (1) pretreating a to-be-detected sample; (2) activity determination; (3) relative tissue activity judgment; (4) measuring the expression quantity of cell factors; (5) judging the expression quantity of relative cell factors; and (6) judging an eye irritation result. According to the method, the expression quantity of cell factors is increased to serve as the evaluation standard of the eye irritation, the evaluation accuracy of the eye irritation of the sample is remarkably improved, the samples which are judged to be free of eye irritation in relative tissue activity detection can be effectively recognized, then the attention of product developers and supervisors is aroused, and the health of a user is better protected.

The invention provides application of injectable bioactive hydrogel in treatment of recurrent abortion, and relates to the technical field of biomedicine, and the technical key points are as follows: aldehydic hyaluronic acid and chitosan are connected in parallel, the injectable bioactive hydrogel is developed, and the hydrogel is loaded with LIF, VEGF, IL-11 and valproic acid to enhance regeneration activity. According to the application, the effect is evaluated in vitro through a specific verification experiment. Results show that the hydrogel prepared by the application shows rapid gelation, good biocompatibility and factor loading capacity, and enhances the proliferation of human endometrial stromal cells and the vascularization capacity of human umbilical vein endothelial cells. In macrophages, the expression of a proinflammatory cytokine is down-regulated, and the expression of an anti-inflammatory cytokine IL-10 is up-regulated. In conclusion, the HA-CHO / chitosan hydrogel in the application supports endometrial regeneration by synergistically promoting proliferation, angiogenesis, immune regulation and receptivity.

The invention belongs to the technical field of novel application of nattokinase, and provides application of nattokinase in preparation of a medicine for preventing and / or treating Parkinson's disease. According to the invention, an MPTP / MPP + induced Parkinson's disease (PD) in-vivo and in-vitro model is established, and a neuroprotection mechanism of nattokinase is disclosed by adopting a systematic experiment method. Results show that the nattokinase can significantly improve dyskinesia and intestinal dysfunction of MPTP-induced PD mice; the damage of dopaminergic neurons of the middle brain is effectively relieved, and the density of tyrosine hydroxylase positive neurons is maintained; the expression of TLR4 and NLRP3 inflammasome pathways and related proinflammatory cytokines is inhibited, and the neuroinflammatory response is relieved; pINK1 / Parkin expression is up-regulated, mitochondrial autophagy is activated, and damaged neurons are cleared. Direct association between nattokinase and Parkinson's disease prevention and treatment is established for the first time, an innovative solution is provided for developing a novel anti-Parkinson's disease medicine with dual effects of motor function improvement and neuroprotection, and the application has important development value in the field of treatment of neurodegenerative diseases.

The invention discloses application of a pain and diarrhea prescription to regulation and control of a BLP + macrophage subgroup to treat IBS-D. The pain and diarrhea prescription contains a liver soothing component (6-10 parts of pericarpium citri reticulatae and 6-10 parts of radix saposhnikoviae) and a spleen tonifying component (10-15 parts of rhizoma atractylodis macrocephalae and 10-15 parts of radix paeoniae alba) or a combination of the liver soothing component and the spleen tonifying component according to the ratio of 1: (1-2). By promoting the expression of anti-inflammatory cytokines IL-10 and TGF-beta, inhibiting the expression of pro-inflammatory cytokines IL-6 and TNF-alpha, activating an AMPK signal channel, inhibiting an NF-kappa B signal channel and promoting the expression of colonic mucosal barrier indexes ZO1 and OCLN, a colonic mucosal barrier is repaired, and the symptoms of IBS-D abdominal pain and diarrhea are relieved. The invention also provides a pharmaceutical composition containing the key active component, and the dosage forms comprise an aqueous solution, a tablet and the like. The traditional Chinese medicine composition solves the problems of large toxic and side effects, poor compliance and unknown mechanism in the existing IBS-D treatment, is definite and safe in curative effect, and has important clinical value and scientific significance.

The gut microbiota produces a wide variety of metabolites, which interact with intestinal cells by modulating either gene transcription or post-translational modifications of gut proteins. The effect of gut commensal bacteria on SUMOylation, an essential ubiquitin-like modification in intestinal physiology, remains however unknown. Here, the inventors show that branched chain fatty acids (BCFAs) increase protein SUMOylation in different intestinal cell lines. They demonstrated that the hyperSUMOylation induced by BCFAs inhibits the activation of the NF-κB pathway by blocking the degradation of the inhibitory factor IκBα in response to TNFα. This results in a decrease in pro-inflammatory cytokines expression as well as a decrease in intestinal epithelial permeability in response to TNFα. Accordingly, the present invention relates to the use of Branched Chain Fatty Acids (BCFAs) for the treatment of diseases associated with intestinal inflammation such as Inflammatory Bowel Diseases and Irritable Bowel Syndrome.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The invention belongs to the technical field of biology, and discloses application of farrerol in preparation of an intestinal micro-ecological regulator and a medicine for treating colorectal cancer. The farrerol provided by the invention can effectively enhance the tumor immune killing effect of a body by changing the intestinal microecology, inhibiting the growth of tumor cells, regulating and controlling the expression of cell factors, regulating the inflammation level of a tumor tissue microenvironment and other biological activities; the compound has good potential of being used as a medicine for treating the colorectal cancer and / or an enhancer of ICIs for treating the colorectal cancer.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

Disclosed are nucleic acids comprising a nucleotide sequence encoding a polypeptide comprising a cytokine, or a functional portion of the cytokine; a transmembrane-intracellular amino acid sequence or a transmembrane amino acid sequence; and an immunomodulatory imide drug (IMiD)-degradable degron, wherein the nucleotide sequence encoding the polypeptide comprises a promoter operatively associated with the nucleotide sequence encoding polypeptide. Also disclosed are related recombinant expression vectors, viral particles, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of enhancing the immune response to a cancer.

The invention discloses a production method of mesenchymal stem cells applied to anti-aging, and relates to the technical field of cell biologication.The production method of the mesenchymal stem cells applied to anti-aging comprises the following steps that S1, cell culture is conducted, specifically, mesenchymal stem cells are cultured in vitro till the cell fusion degree reaches 60%-95%; s2, cytokine stimulation: adding cytokines into the cultured cell culture medium, and stimulating for 24-48 hours; s3, detecting and screening: digesting and collecting the mesenchymal stem cells, detecting the expression level of indoleamine 2, 3-dioxide oxidase and related cytokines in the mesenchymal stem cells, and detecting the immune regulation ability of T cells; the mesenchymal stem cells obtained by adopting the production method of the mesenchymal stem cells applied to anti-aging provided by the invention have a better anti-aging effect, the immune regulation ability and the specific factor secretion level of the mesenchymal stem cells are improved by adding cytokines, the production method of the mesenchymal stem cells is established, and the mesenchymal stem cells can be used for preparing the anti-aging mesenchymal stem cells. The pharmaceutical composition is applied to anti-aging related diseases.

The invention belongs to the field of biotechnology and tumor immunotherapy, and particularly relates to a cancer vaccine based on attenuated listeria monocytogenes (LADS) and application of the cancer vaccine. Specifically, wild listeria monocytogenes (e.g., EGD-e) or attenuated listeria monocytogenes (LADS) are taken as an original strain, and an hly gene sequence or a fragment thereof in the original strain is replaced with polynucleotide of a fusion protein coding sequence containing LLO mutants (LLON478A + V479A) and TT856-1313, so that the recombinant attenuated listeria monocytogenes strain is obtained. Compared with wild listeria monocytogenes, the recombinant attenuated listeria monocytogenes strain has the advantages that the growth activity is not obviously changed, but the toxicity is obviously reduced; the polypeptide has cell infection ability, but has biological safety in a body and tends to colonize tumor tissue. Furthermore, the recombinant attenuated listeria monocytogenes strain can effectively inhibit the growth of cervical cancer and colon cancer, and can significantly induce immune response in a tumor microenvironment (e.g., significantly enhance cytokine expression).

A fermentation process is disclosed that produces an immunomodulatory product. The process includes combining a source of starch, a source of sugar, and a source of a trace mineral with probiotic microorganisms and fermenting aerobically and anaerobically, thereby producing an immunomodulatory product. Turmeric is added before or after fermentation. The immunomodulatory product is also disclosed. Also provided are uses of the immunomodulatory product, such as to decrease inflammation in a subject. These methods can include increasing function of natural killer cells, decreasing T cell activation, altering CD69 expression on immune cells, and / or altering cytokine expression in a subject.

The invention discloses an application of green tendon relaxing ketone in preparation of a medicine for treating rheumatoid diseases. The invention proposes and verifies that the green tendon relaxing ketone can effectively promote fibroblast-like synovial cell ferroptosis so as to inhibit synovial hyperplasia and inhibit the expression of proinflammatory cytokines so as to effectively relieve the progress of rheumatoid arthritis for the first time, and has an excellent application prospect in clinical treatment of rheumatoid diseases.

The invention discloses a lactobacillus plantarum RT1 with an anti-inflammatory effect and application of the lactobacillus plantarum RT1. The lactobacillus plantarum RT1 with the anti-inflammatory effect is screened by utilizing a J774-Dual macrophage inflammation model, the influence of the RT1 on the cell activity is evaluated, and the anti-inflammatory effect of the lactobacillus plantarum RT1 is researched. It is found that the lactobacillus plantarum RT1 significantly inhibits LPS and salmonella induced NF-kappa B activation, inhibits expression of pro-inflammatory cytokines IL-1beta, TNF-alpha and IL-6, meanwhile up-regulates the expression level of an anti-inflammatory cytokine IL-10, and maintains good cell activity; dSS-induced weight loss, occult blood, colon shortening and DAI score are significantly relieved, the MPO level and inflammatory cytokine expression are reduced, and colon tissue pathological damage is improved. The lactobacillus plantarum RT1 has the function of inhibiting intestinal inflammation, so that a new material is provided for the development of novel efficient anti-inflammatory probiotics.

This invention relates to the field of natural product pharmaceuticals, and more particularly to a spirobroussonin compound, its preparation method, and its application. The spirobroussonin C provided by this invention is isolated from the paper mulberry tree. This compound can inhibit the release of the inflammatory factor IL-13 from human keratinocytes induced by IL-4 / TNF-α, exhibiting activity superior to the clinical drug dexamethasone and without cytotoxicity. It can significantly alleviate ear dryness and excessive angiogenesis in MC903-induced atopic dermatitis mice, reduce ear swelling, epidermal thickening, and transepidermal water loss, alleviate the trend of weight loss, reduce mast cell infiltration, and inhibit the expression of serum IgE and Th2-type cytokines such as IL-13, IL-4, and TSLP in ear tissue. No glucocorticoid-like side effects such as skin atrophy or metabolic disorders were observed with Spirobroussonin C within the experimental dose range.

The present invention relates to an anti-inflammatory composition comprising, as an active ingredient, a lipid extract of Oncorhynchus mykiss eggs. The anti-inflammatory activity of the lipid extract of Oncorhynchus mykiss eggs, of the present invention, was confirmed by analyzing the fatty acid composition and cytotoxicity of the lipid extract of Oncorhynchus mykiss eggs, and the effects thereof on inhibiting NO production, regulating the expression of cytokines, inhibiting NF-κB and MAPK activation, and inhibiting CD86 expression on the surface of immune cells.

The invention discloses Lactobacillus johnsonii and application thereof in alleviating intestinal damage caused by plateau hypoxia. The composite bacterial agent of the composition of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can effectively prevent, treat and alleviate intestinal damage caused by plateau hypoxia exposure. The composite bacterial agent can increase the expression levels of tight junction proteins such as Claudin‑1, Occludin and ZO‑1, and restore the intestinal barrier function damage caused by plateau hypoxia exposure; restore the expression level of intestinal pro-inflammatory cytokines; reduce the level of harmful bacteria Escherichia coli, and increase the level of beneficial bacteria Lactobacillus; improve diarrhea; and maintain body weight. The composite bacterial agent provided by the invention can be used to prepare a medicine for alleviating intestinal damage caused by plateau hypoxia exposure and a composition thereof, can also be used as an auxiliary product of existing therapeutic drugs and treatment methods, and can also be used as a microecological preparation in medicines or health products, and has a very broad application prospect.

The present invention relates to a therapeutic composition for inhibiting the activity of a systemic sclerosis waveform protein variant using a STAT6 inhibitor, and has been confirmed that the STAT6 inhibitor inhibits the expression of fibrotic T cells and M2 macrophages, which are immune cells associated with systemic sclerosis, increases the expression of Treg, and inhibits the expression of fibrotic T cells and M2 macrophages, which are immune cells associated with systemic sclerosis. It has been confirmed that the expression of TGF-beta, Col1a1, and alpha-SMA, which are fibrosis factors associated with systemic sclerosis, is inhibited. Moreover, it has been confirmed that the expression of cell surface waveform protein, which is a waveform protein variant associated with systemic sclerosis, is reduced in skin tissue and lung tissue, and it has been confirmed that the waveform protein variant can be regulated. In addition, the presence of pSTAT6-expressed CD8T cells is confirmed in fibrotic tissues, and the expression of pSTAT6-expressed CD8T positive cells is confirmed to be regulated by administration of an STAT6 inhibitor. The STAT6 inhibitor also has been confirmed to inhibit the tissue fibrosis of systemic sclerosis in which the antigen-specific disease activity is increased in an animal model with increased waveform protein-specific disease activity, and to inhibit the expression of CD8-positive TRM expressed by an IL-17 cytokine capable of inducing inflammation and fibrosis, which is a systemic sclerosis cause cell.

The present invention pertains to a Lonicera japonica flower water extract composition for preventing or treating Helicobacter pylori infection, the composition containing secoxyloganin as an active ingredient. The extract contains a specific amount of secoxyloganin, and thus exhibited excellent antibacterial effects when used on Helicobacter pylori bacteria, and exhibited excellent effects in terms of reducing Helicobacter pylori IgG antibody expression in the blood, alleviating histopathological lesions, and reducing cytokine expression when used on Helicobacter pylori-infected mice. Thus, the Lonicera japonica flower water extract of the present invention can be usefully used as a composition for preventing or treating Helicobacter pylori infection.

Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.

The present invention provides a method for sample pretreatment and preservation for cytokine flow detection of rheumatism patients, and a diagnostic kit for determining the type of autoimmune disease and diagnosing autoimmune diseases (such as rheumatism). Specifically, the method and kit provided by the present invention have clinical significance for improving the stability and accuracy of cytokine detection results based on flow cytometry in rheumatism patients. In addition, the method established according to the particularity of cytokine expression in the bodies of rheumatism patients has accurate detection results, good repeatability, and is easy to be clinically popularized and applied.

The present invention relates to a microbiome composition of the fermentation culture supernatant of Lactiplantibacillus plantarum KM2 strain, which has anti-inflammatory effects. It has been confirmed that the fermentation culture supernatant of the strain exhibits anti-inflammatory activities such as suppressing nitric oxide activity and regulating the expression of inflammatory cytokines, and therefore can be useful as a composition for preventing, treating, or ameliorating inflammatory diseases.

[Problem] To provide an inflammatory cytokine expression inhibitor or the like that can effectively suppress the expression amount of inflammatory cytokine and that can be used safely without any risks of side effects. [Solution] This inflammatory cytokine expression inhibitor contains nicotinamide mononucleotide as an active ingredient.

The invention discloses an application of Rubiasin A in preparation of a medicine for preventing and treating lung injury. The invention proposes and verifies that Rubiasin A can achieve the effect of protecting the activity of pulmonary epithelial cells through the synergistic effect in three directions of relieving oxidative stress injury, inhibiting expression of pro-inflammatory cytokines and recovering mitochondrial functions of cells for the first time, so that acute lung injury is effectively relieved, and the Rubiasin A is a natural medicine with great application potential.